Laboratory Corporation of America Holdings
F:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Laboratory Corporation of America Holdings
F:LAB
|
US |
|
K
|
Knowledge Atlas Technology JSC Ltd
HKEX:2513
|
CN |
|
Metro Mining Ltd
OTC:MMILD
|
AU |
|
I
|
Isetan Mitsukoshi Holdings Ltd
XBER:4HP
|
JP |
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings, better known as Labcorp, is a major medical testing company. It runs laboratories that analyze blood, urine, tissue, and other samples for doctors, hospitals, and health systems. It also works with drug makers to test new medicines during development and to support clinical trials. Labcorp makes money in two main ways: by charging for routine diagnostic tests and by charging pharmaceutical and biotech customers for drug development and trial testing services. Its customers include physicians ordering lab work for patients, hospitals, insurers and managed care groups that rely on test results, and life sciences companies that need laboratory support for research and regulatory studies. What makes Labcorp different is that it sits in the middle of both everyday healthcare and pharmaceutical research. On the healthcare side, it helps doctors find and monitor disease. On the drug-development side, it helps companies prove whether a medicine is safe and effective. That combination gives it a broad role in the medical testing chain rather than simply being a single-product company.
Laboratory Corporation of America Holdings, better known as Labcorp, is a major medical testing company. It runs laboratories that analyze blood, urine, tissue, and other samples for doctors, hospitals, and health systems. It also works with drug makers to test new medicines during development and to support clinical trials.
Labcorp makes money in two main ways: by charging for routine diagnostic tests and by charging pharmaceutical and biotech customers for drug development and trial testing services. Its customers include physicians ordering lab work for patients, hospitals, insurers and managed care groups that rely on test results, and life sciences companies that need laboratory support for research and regulatory studies.
What makes Labcorp different is that it sits in the middle of both everyday healthcare and pharmaceutical research. On the healthcare side, it helps doctors find and monitor disease. On the drug-development side, it helps companies prove whether a medicine is safe and effective. That combination gives it a broad role in the medical testing chain rather than simply being a single-product company.
Strong quarter: Labcorp reported first-quarter revenue of $3.5 billion, up 5.8%, with adjusted EPS up 10.6% and margin expansion of more than 30 basis points.
Guidance raised: Management lifted the midpoint of full-year enterprise revenue by about $30 million and EPS by $0.13, while keeping free cash flow guidance unchanged at $1.24 billion to $1.36 billion.
Diagnostics momentum: Diagnostics revenue grew 5% to $2.8 billion, helped by specialty testing, higher test-per-assessment, and acquisitions, though weather held back volumes.
BLS strength: Biopharma Laboratory Services revenue rose 8.2% to $781 million, driven by Central Labs, and management expects sequential improvement in book-to-bill in the second quarter.
Strategic focus: The company highlighted ongoing hospital and health system partnerships, specialty testing expansion, and new AI and digital tools as key growth drivers.
Policy watch: Management said the ACA exchange impact was immaterial in the quarter but still expects a 30 basis point diagnostic volume headwind for the year, and it remains active on PAMA and the RESULTS Act.
